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EGF-Stimulation Activates the Nuclear
Localization Signal of SHP-1
Dandan He, Xi Song, Lijun Liu, David H. Burk, and G. Wayne Zhou*
Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana 70803
Abstract
Protein tyrosine phosphatase SHP-1 plays a critical role in the regulation of a variety of intracellular
signaling pathways. SHP-1 is predominantly expressed in the cells of hematopoietic origin, and is recognized as a negative
regulator of lymphocyte development and activation. SHP-1 consists of two Src homology 2 (SH2) domains and one
protein tyrosine phosphatase (PTP) domain followed by a highly basic C-terminal tail containing tyrosyl phosphorylation
sites. It is unclear how the C-terminal tail regulates SHP-1 function. We report the examination of the subcellular
localization of a variety of truncated or mutated SHP-1 proteins fused with enhanced green fluorescent protein (EGFP)
protein at either the N-terminal or the C-terminal end in different cell lines. Our data demonstrate that a nuclear
localization signal (NLS) is located in the C-terminal tail of SHP-1 and the signal is primarily defined by three amino-acid
residues (KRK) at the C-terminus. This signal is generally blocked in the native protein and can be exposed by fusing EGFP
at the appropriate position or by domain truncation. We have also revealed that this NLS of SHP-1 is triggered by epidermal
growth factor (EGF) stimulation and mediates translocation of SHP-1 from the cytosol to the nucleus in COS7 cell lines.
These results not only demonstrate the importance of the C-terminal tail of SHP-1 in the regulation of nuclear localization,
but also provide insights into its role in SHP-1-involved signal transduction pathways. J. Cell. Biochem. 94: 944–953,
2005. ß 2004 Wiley-Liss, Inc.
Key words: protein tyrosine phosphatase SHP-1; nuclear localization signal; epidermal growth factor; subcellular
translocation

Protein tyrosine phosphorylation governs
enzymatic activation, protein relocalization,
and formation of the signaling protein complexes in many signaling pathways. Formation
of these complexes is critical in the control of
normal cell behavior such as cell growth, cell
differentiation, and apoptosis [Neel, 1993;
Tonks and Neel, 1996, 2001; Neel and Tonks,
1997; Tsui et al., 2002]. Protein tyrosine
phosphorylation is regulated by two types of
enzymes: protein tyrosine kinases (PTKs) that
catalyze the phosphorylation, and protein tyrosine phosphatases (PTPs) that are responsible
for dephosphorylation [Van Vactor et al., 1998;
Neel et al., 2003]. Abnormal tyrosine phosphor-
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ylation levels may cause cell disorders including
various cancers [Wu et al., 2003a,b]. PTPs play
critical roles in regulating intracellular processes in response to extracellular signals and
stimuli including antigens, cytokines, growth
factors, and hormones, as well as intracellular
signals such as DNA damage [Yi et al., 1993;
Keilhack et al., 1998, 2000; Yoshida et al., 1999].
SHPs, including SHP-1, SHP-2, Csw from
Drosophila and PTP-2 from Caenorhabditis
elegans are a family of Src homology 2 (SH2)
domain-containing non-receptor like PTPs.
SHP-1 and SHP-2 have highly homologous
primary structures (overall 55% identity), and
both are composed of two tandem SH2 domains
and one PTP catalytic domain, followed by a
C-terminal tail. Biochemical and structural
analyses have contributed significantly to elucidation of the critical role of SH2 domains for
SHP-1 and SHP-2 [Tenev et al., 1997; Barford
and Neel, 1998; Hof et al., 1998; Tsui et al., 2002;
Yang et al., 2003]. Crystallographic studies on
derivatives lacking the C-terminal tail revealed
a similar auto-inhibition conformation for these
two enzymes [Hof et al., 1998; Yang et al., 2003].
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However, SHP-1 and SHP-2 differ greatly in
cellular distribution and biological function.
SHP-1 is predominantly expressed in hematopoietic cells and epithelial cells, and behaves as
a negative regulator in the B- and T-cell activation signaling pathways. In contrast, SHP-2
is expressed ubiquitously in cells with various
origins and acts primarily as a positive regulator [Plutzky et al., 1992]. Interestingly, the Cterminal tail region (60 residues) of these two
enzymes shows lower sequence homology
(15% identity) than the overall homology
(Fig. 1a). Therefore, the difference in the Cterminal tails of SHPs, could be responsible, at
least in part, for the differences between them in
function and subcellular localization. However,
the structure and function of the C-terminal tail
remains unknown, primarily due to the lack of
full-length SHP structures.
There are two tyrosyl phosphorylation sites
(Tyr536 and Tyr564) on the C-terminal tail of
SHP-1. Recent studies revealed the importance
of these tyrosine phosphorylation sites, supporting the idea that the C-terminal tail of SHP1 functions in the regulation of its activity and
substrate recognition [Pei et al., 1994; Zhang
et al., 2003]. The C-terminal tail of SHP-1 is
highly basic; 30% of the residues are lysines or
arginines (Fig. 1a). This region, identified by
two groups, contains a nuclear localization
signal (NLS) that controlled the subcellular
localization of SHP-1 [Craggs and Kellie, 2001;

Yang et al., 2002]. One group reported that the
C-terminal tail contained an NLS that targets
SHP-1, in a cell-type dependent-fashion, to the
cytosol of hematopoietic cells but to the nuclei of
non-hematopoietic cells. This NLS of SHP-1 was
identified as the last three amino acids (KRK) at
the C-terminus [Craggs and Kellie, 2001]. In
contrast, another group reported that SHP-1
was located in the cytosol and could be in part
translocated into nuclei in response to cytokine
activation, regardless of cell type. Also, in the
latter case, a bipartite NLS was suggested to
exist in the C-terminal tail region [Yang et al.,
2002]. Thus different, even contradictory, subcellular localization patterns of SHP-1 were
observed within different cell lines under different physiological conditions, implying there
is complexity in the function of the C-terminal
tail of SHP-1.
In order to define more carefully about the
role of the C-terminal NLS on subcellular
localization of SHP-1, we have examined the
localization of different forms of SHP-1 in a
variety of cell lines. Our data confirm the
presence of an NLS in the C-terminal tail of
SHP-1 and define it as the triple amino-acid
cluster KRK at the C-terminus. We have also
demonstrated that variation in how SHP-1 is
fused to enhanced green fluorescent protein
(EGFP) can explain the contradictory reports on
SHP-1’s subcellular distribution. Our results
further support the important role of the KRK

Fig. 1. C-terminal tail of SHPs and scheme of the SHP-1
constructs. a: Sequence alignment of the C-terminal tails of SHP1 and SHP-2. Identical residues are red, lysine and arginine
residues are green, and tyrosine phosphorylation sites are labeled.
b: SHP-1 constructs designed for nuclear localization studies, fulllength SHP-1 (SHP-1), SHP-1 with the three residues at C-terminus

mutated to AAA (SHP-1-AAA), SHP-1 C-terminal tail (SHP-1-T),
SHP-1-T with last three residues mutated into AAA (SHP-1-TAAA), and C-terminal truncated SHP-1 (SHP-1-DT). [Color figure
can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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cluster on SHP-1 nuclear translocation and
suggest the blocking of the NLS, unless translocation is activated. We have also shown that the
blocked NLS was released with EGF stimulation, resulting in the translocation of the SHP-1
protein into nuclei in COS7 cell lines.
MATERIALS AND METHODS
Preparation of EGFP Fused Constructs
The coding sequences of full-length SHP-1
(SHP-1), C-terminal truncated SHP-1 (residues
1-532, SHP-1-DT), SHP-1 with KRK at C-terminus mutated to AAA (SHP-1-AAA), C-terminal tail of SHP-1 (residues 533-595, SHP-1-T),
and C-terminal tail with the KRK cluster
mutated to AAA (SHP-1-T-AAA) were generated by polymerase chain reaction (PCR) with
Platinum Pfx polymerase as described previously (Fig. 1b) [Liang et al., 1997]. These
coding sequences were cloned into pEGFP-N1
and pEGFP-C2 vectors (Clontech) with the
cleavage of XholI and HindIII sites at the 50
end and 30 end of the corresponding PCR
products, to obtain the N- and C-terminally
EGFP-fused constructs, respectively. All cloned
plasmids were confirmed by DNA sequencing.
Cell Culture
All cell lines were obtained from American
Type Culture Collection and maintained at 378C
in a humidified 5% CO2 incubator. HEK293,
COS7, A431, and HT 29 were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS,
Life Technologies, Inc.), 100 units/ml penicillin,
and 100 mg of streptomycin (Life Technologies,
Inc.) HepG2 cells were maintained in minimum
essential medium (Eagle) with 2 mM L-glutamine and Eagle’s BSS, and 10% FBS, whereas
H9 and Raji cells were grown in RPMI 1640 with
10% FBS and 2 mM L-glutamine.
EGF-Stimulation and Extraction
of Cell Fractions
COS7 cells were transiently transfected with
pEGFP-SHP-1 using lipofectamine (Invitrogen)
for 6 h, and grown in complete medium for 24 h.
For further treatment, cells were serumstarved for 3 h, and treated with epidermal
growth factor (EGF, 100 ng/ml) (Calbiochem)
for 1, 3, and 5 min. To prepare cytoplasmic and
nuclear fractions, EGFP-SHP-1 transfected
COS-7 cells were lysed in buffer A (10 mM

Tris-HCl, pH 7.8, 1.5 mM MgCl2, 10 mM KCl,
1 mM benamidine, 0.1 mM phenylmethylsulfonyl fluoride, 20 mg/ml leupeptin, 1 mM pepstain
A, 1 mg/ml aprotinin, and 1 mM DTT) for 15 min
on ice, then added 10% NP-40, mixed for 10 s
and centrifuged at 8,000 rpm for 1 min, to
separate the nuclear pellet from the cytoplasmic
supernatant. The nuclear pellet was re-suspended in the buffer C (20 mM HEPES, pH 7.9,
400 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0.1 mM phenylmethylsulfonyl fluoride, and
1 mM DTT) for 45 min on ice, and centrifuged
at 14,000 rpm for 10 min. The cytoplasmic
and nuclear fractions were analyzed by SDS–
PAGE and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes
were blocked in TBST buffer (10 mM Tris-HCl,
pH 8.0, 150 mM NaCl, and 0.1% Tween-20) with
5% non-fat dry milk for 1 h at room temperature.
Then they were incubated with anti-SHP-1
rabbit polyclonal antibody [Liang et al., 1997],
followed by incubation with AP-conjugated
secondary antibodies and detection with
enhanced chemiluminescence (ECL) kit. The
amounts of histone H1 and tubulin (Santa Cruz)
were identified in the corresponding samples by
Western analysis and were used as nuclear and
cytosolic markers, respectively.
Immunocytochemistry
and Fluorescence Microscopy
Cells were grown on glass coverslips and
transfected with the corresponding plasmid
DNA by lipofectinamine reagent. Thereafter,
cells were grown in complete medium for 24 h.
For lymphoma cells (H9), transfected cells were
spun onto glass coverslips at 500 rpm for 5 min
using a Cytospin 3 rotor. For further treatment,
COS7 and A431 cells were serum-starved for
3 h, and then treated with EGF (100 ng/ml) for
5 min. Cells were fixed with 4% formaldehyde in
PBS for 20 min. After extensive washing with
PBS, cells were mounted with Vectashield
mounting medium (Vector). To visualize endogenous SHP-1, A431, HT29, HepG2, and Raji
cells were fixed with 4% paraformaldehyde in
PBS for 20 min and permeabilized with PBS
containing 1% FBS and 0.5% TritonX-100, then
incubated with anti-SHP-1 rabbit polyclonal
antibody for 2 h at room temperature. The cells
were washed three times for 10 min each in PBS
before fluorescein isothiocyanate anti-rabbit
antibody (1:1,000) (Biosource) was applied for
30 min. After washing three times with the
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same buffer, the coverslips were mounted with
the same mounting medium. All mounted cells
were examined using a MRC1024 confocal
microscope (Bio-Rad). Images were captured
with Adobe Photoshop.
RESULTS
NLS on the C-Terminal Tail of SHP-1
An NLS on the C-terminal tail of SHP-1 has
been reported before. However, the NLS
affected nuclear localization differently in two
independent studies. Craggs’ group, using a
site-directed mutagenesis approach, suggested
that the NLS was primarily determined by a
KRK cluster located at the C-terminus of SHP-1
[Craggs and Kellie, 2001], whereas Yi’s group,
through examination of the localization of a
series of constructs of different lengths, identified that the NLS functions in an apparently
bipartite fashion, which is composed of two
separate basic clusters on the C-terminal tail
[Yang et al., 2002]. To further examine the NLS,
the SHP-derivatives SHP-1-AAA, SHP-1-T,
SHP-1-T-AAA, and SHP-1-DT; and the entire
SHP-1 coding region were (Fig. 1b) fused with
EGFP at the C-terminal end and transfected
into a human embryonic kidney cell line
(HEK293) and a human T lymphoma cell line
(H9). The subcellular distribution of SHP-1 and
its derivatives was determined (Fig. 2).
SHP-1 (Fig. 2a), as well as SHP-1-T (Fig. 2c),
was localized within the nuclei of all HEK293
cells examined. However, the C-terminal tail

Fig. 2. Subcellular localization of SHP-1 from different constructs in representative hematopoietic and non-hematopoietic
cells. The localization of C-terminally EGFP-tagged full-length
SHP-1, SHP-1-AAA, SHP-1-T, SHP-1-T-AAA and SHP-1-DT was
compared in HEK293 cells (upper row, non-hematopoietic) and
H9 cells (bottom row, hematopoietic). In HEK293 cells, SHP-1 (a)
and SHP-1-T (c) showed a nuclear distribution, SHP-1-AAA (b)
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truncated SHP-1 (SHP-1-DT), and the constructs with the KRK cluster mutated to AAA
(SHP-1-AAA and SHP-1-T-AAA) were either
localized mainly in the cytoplasm of HEK293
cells (SHP-1-AAA, Fig. 2b and SHP-1-DT,
Fig. 2f) or distributed like EGFP (Fig. 2e)
throughout the cells (SHP-1-T-AAA, Fig. 2d).
Consistent with the observations from Craggs’
group [Craggs and Kellie, 2001], our results
confirmed that the NLS of SHP-1 was located at
the C-terminal tail and that the KRK cluster at
the C-terminus was required for nuclear localization. In contrast, in hematopoietic cells, all
the SHP-1 constructs had a clear cytosolic
localization (H9 cells, Fig. 2g–k; data for K562
and Romas cells is not shown). These findings
demonstrate that the subcellular localization of
SHP-1 is cell-type dependent, and SHP-1 is
localized in the cytoplasm of hematopoietic cells
and in the nuclei of non-hematopoietic cells.
Subcellular Localization of SHP-1 Depends
on the Position of Fused EGFP
As described above, subcellular localization
of SHP-1 has been studied previously. Both
groups demonstrated the cytosolic distribution
of EGFP-fused SHP-1 in hematopoietic cells.
However, in non-hematopoietic cells, the
results from two groups were contradictory:
one demonstrated nuclear distribution and the
other demonstrated cytosolic distribution of
SHP-1. The major differences between two
groups were that EGFP was fused at the Nterminus and the C-terminus of SHP-1, respec-

and SHP-1-DT (f) showed a clear cytosolic distribution, and SHP1-T-AAA (d) showed a similar distribution to EGFP only (e). In
contrast, SHP-1 (g), SHP-1-AAA (h), SHP-1-T (i) and SHP-1-TAAA (j) showed cytosolic distribution similar to that of EGFP (k) in
H9 cells. [Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
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tively, and the studies were carried in different
cell lines. Those differences might be the
primary reasons for the conflicting results. To
test this hypothesis, both N-terminally and Cterminally EGFP-fused SHP-1 (EGFP-SHP-1
and SHP-1-EGFP) were cloned and transiently
transfected into a variety of cell lines (Fig. 3).
Surprisingly, EGFP-SHP-1 and SHP-1-EGFP
had similar distributions in cancer cell lines but
had much different localization in normal cell
lines. In cancer cell lines (A431 and HT29 cell
lines), both EGFP-SHP-1 and SHP-1-EGFP
were localized in the cytoplasm (Fig. 3c–d &
g–h). The observed cytosolic distribution of
SHP-1 in A431 cell lines is consistent with the
previously reported perinuclear distribution of
SHP-1 in A431 cells [Tenev et al., 2000].
However, in normal cell lines such as HEK293
cells and monkey embryonic kidney (COS7)
cells, SHP-1-EGFP was localized in the nuclei
(Fig. 3e–f), whereas EGFP-SHP-1 was predominantly localized in the cytoplasm (Fig. 3a–b).
This clear difference on SHP-1’s distribution
within normal cell lines can explain the contradictory results from the Craggs (C-terminally
EGFP-fused SHP-1) and Yi (N-terminally EGFPfused SHP-1) groups [Craggs and Kellie, 2001;

Yang et al., 2002]. The results suggest that the
distribution of EGFP-fused SHP-1 in normal
cells depend on whether EGFP is fused to the Nor C-terminus.
To further examine the potential dependence
of NLS activity on the position of the fused
EGFP protein, derivatives of the SHP-1 Cterminal tail construct (SHP-1-T) were made
carrying EGFP fused to either the N-terminus
EGFP-SHP-1-T or the C-terminus (SHP-1-TEGFP) (see Fig. 1b). These constructs were
transiently transfected into HEK293 and COS7
cell lines. Interestingly, both EGFP-SHP-1-T
(Fig. 4a–d) and SHP-1-T-EGFP (Fig. 4e–h)
showed nuclear localization in these cell lines,
implying that when only the C-terminal tail is
expressed the NLS is unaffected by the position
of EGFP.
One possible explanation for the observed
difference is that the NLS (KRK) at the Cterminal tail of SHP-1 is blocked in the native
SHP-1 structure, possibly through binding to or
being buried in an acidic cavity on the surface of
SHP-1 protein itself, or on the surface of other
SHP-1 binding proteins. Therefore, when EGFP
was fused to the N-terminus of SHP-1, the NLS
at the C-terminus was still blocked and buried,

Fig. 3. Subcellular localization of SHP-1 with EGFP-tag at
different positions. The localization of EGFP-SHP-1 (upper, EGFP
tagged at N-terminus of SHP-1) and SHP-1-EGFP (lower, EFGF
tagged at C-terminus of SHP-1) was compared in normal cell
lines (HEK293 and COS7) and cancer cell lines (A431 and HT29).

EGFP-SHP-1 showed a cytosolic localization in all these cell
lines (a–d), whereas SHP-1-EGFT showed nuclear localization in
normal cell lines (e, f), but cytosolic distribution in cancer cell
lines (g, h). [Color figure can be viewed in the online issue, which
is available at www.interscience.wiley.com.]
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Fig. 4. Subcellular localization of SHP-1-T with EGFP-tag at the N- or C-terminus. The localization of
EGFP-SHP-1-T (upper, EGFP tagged at N-terminus of SHP-1) and SHP-1-T-EGFP (lower, EGFP tagged at
C-terminus of SHP-1) was compared in HEK293, COS7, A431, and HT29 cell lines. In all these cell lines,
SHP-1-T showed a nuclear localization. [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]

therefore, the fused protein has the cytosolic
distribution. However, when EGFP protein was
fused at the C-terminus of SHP-1, the NLS
would be exposed somehow due to the presence
of EGFP nearby, therefore, the fused protein
has the nuclear distribution. When the Cterminal tail is expressed by itself, the NLS is
exposed, resulting in nuclear distribution, regardless of the position of the fused EGFP.
Therefore, our data, together with the previously published results suggest that the NLS
at the C-terminus of SHP-1 is buried in the basal
state of the native SHP-1 protein. Perhaps
activation signals, such as growth factor stimulated activation, could expose the tail of SHP-1
and target the SHP-1 into the nuclei for its
physiological function.
Translocation of SHP-1 in Response
to EGF Stimulation
SHP-1 has been implicated in the EGFstimulated signal transduction pathway.
SHP-1 is a positive regulator of EGF-induced
activation of signal transducers and activators
of transcription (STAT) [Keilhack et al., 1998;
Tenev et al., 2000]. SHP-1 can also affect the
EGF-induced activation of the mitogen-acti-

vated protein kinase pathway [Keilhack et al.,
1998]. In addition, overexpression of SHP-1
significantly decreased the tyrosine phosphorylation level of EGF receptor, and vise versa,
EGF induced the phosphorylation and recruitment of SHP-1. Furthermore, the inducible
overexpression of SHP-1 attenuated the EGFdependent tyrosine phosphorylation and the
EGF-dependent activation of STAT1/3 DNAbinding activity in the A431 cell line [Tenev
et al., 2000]. These data suggest the possible
interference of SHP-1 with the EGF-receptor
signaling pathway. Therefore, it is of interest to
see whether or not the NLS of SHP-1 can be
activated by EGF-stimulation.
To address this question, the construct with
the N-terminally fused EGFP (EGFP-SHP-1),
whose NLS was blocked under the basal condition, was used for localization studies in A431
and COS7 cell lines (Fig. 5). In the absence of
EGF-stimulation, EGFP-SHP-1 was localized
in the cytosol of both A431 and COS7 cell lines,
as expected from previous results (above).
However, 5 min after EGF-stimulation, different localization was observed in between A431
cell lines and COS7 cell lines. In COS7 cell lines,
SHP-1 was significantly relocalized from cyto-
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Fig. 5. Translocation of SHP-1 in response to EGF-stimulation in A431 (upper) and COS7 (lower) cell lines.
The subcellular localization of SHP-1 is shown prior to EGF-stimulation (EGF) and after EGF-stimulation
(þEGF). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

plasm to nucleus in most cells. In contrast, in
A431 cell lines, EGFP-SHP-1 was still localized
predominantly in the cytoplasm. This result is
consistent with the perinuclear distribution of
SHP-1 in A431 cells reported previously [Tenev
et al., 2000].
To further confirm the EGF-stimulated translocation of SHP-1 in COS7 cells, the amount of
SHP-1 protein in the cytosolic and nuclear
fractions of COS7 cells after EGF-stimulation
were examined using Western blot analysis
(Fig. 6). The cytosolic and nuclear fractions of

Fig. 6. Western blotting of SHP-1 with and without EGFstimulation in COS7 cells. Tubulin and histone H1 were used as
markers for cytoplasm (left) and nucleus (right), respectively.
Western blotting of SHP-1 from COS7 cells with stimulation time
at 0, 1, 3, and 5 min are shown.

the COS7 cells stimulated with EGF for different times were separated as described previously [Yang et al., 2002]. The amount of
SHP-1 proteins in nuclear and cytosolic fractions was examined using the corresponding
antibody. Tubulin and histone H1 were used as
the markers for cytosolic and nuclear fractions,
respectively. Absence of tubulin in the nuclear
fraction and absence of histone H1 in the
cytosolic fraction demonstrated the success of
this separation. In agreement with the results
obtained by immunofluorescence, Western blotting analysis clearly revealed that SHP-1 was
almost absent from the nuclei of COS7 cell lines
(Fig 6, lane 5) prior to EGF-stimulation. In
response to the EGF-stimulation, some SHP-1
protein was translocated into the nuclei, and
this translocation was continued for 5 min. The
amount of SHP-1 protein reached a plateau
more than 5 min after the EGF-stimulation in
COS7 cells (data not shown). However, the same
experiment for A431 cells did not demonstrate
EGF-stimulated translocation of SHP-1 protein
(data not shown), which is consistent with the
immunostaining results (Fig. 5). We conclude
that the nuclear translocation of SHP-1 in
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response to EGF-stimulation occurs, and this
translocation is dependent on cell types.
Subcellular Localization of Endogenous SHP-1
Endogenous SHP-1 is expressed predominantly in the cytosol of hematopoietic cell, as
reported by several different groups [Plutzky
et al., 1992; Yi et al., 1992; Ram and Waxman,
1997; Craggs and Kellie, 2001]. However,
endogenous SHP-1 is localized in the nuclei of
cancer cells of non-hematopoetic origin, such as
Hela cervical adenocarcinoma, A549 lung carcinoma and MCF-7 mammary adenocarcinoma
cell lines [Craggs and Kellie, 2001]. This is
incongruent with our finding of the EGFP-fused
SHP-1 primarily in the cytoplasm of cancer cell
lines (Fig. 3c–d, g–h) and led us to examine the
localization of endogenous SHP-1 in different
carcinoma cell lines with the immunocytochemical method. As reported before, immunostaining with SHP-1-specific antibody reveals a clear
cytosolic distribution of endogenous SHP-1 in
hematopoietic cell lines (Raji) (Fig. 7). However,
in the human epithelial carcinoma cells (A431),
human colonic adenocarcinoma cells (HT29),
and human hepatocellular carcinoma cells
(HepG2), endogenous SHP-1 is localized mainly
in cytoplasm (Fig. 7), with a perinuclear but not
nuclear distribution. Our observation, though is
different from Cragg’s group [Craggs and Kellie,
2001], is consistent with previous observations
in A431 and COS7 cell lines [Tenev et al., 2000].
DISCUSSION
The C-terminal tail of SHP-1 is indispensable
for the regulation of SHP-1-regulated signal
transduction pathways. This highly basic tail
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containing a pair of tyrosyl phosphorylation
sites has been shown to regulate the enzymatic
activity and nuclear localization of SHP-1 [Pei
et al., 1994; Craggs and Kellie, 2001; Yang et al.,
2002; Zhang et al., 2003]. Our studies here have
focused on the role of this C-terminal tail in
nuclear localization.
With different constructs of EGFP-fused
SHP-1, we have confirmed the published reports that an NLS is located at the C-terminal
tail of SHP-1, and this signal is defined by the
KRK at the C-terminus [Craggs and Kellie,
2001; Yang et al., 2002]. In addition, we have
demonstrated that endogenous SHP-1, regardless of cell type, has a cytosolic distribution
(Fig. 7). However, the EGFP-fused SHP-1 shows
varied subcellular localizations, depending on
the position of the fused-EGFP and/or on the cell
type. Our results suggest that the NLS is
blocked in the native state, and the signal could
be triggered by exposing the NLS onto the
surface. Fusing EGFP at the C-terminus of
SHP-1 or expressing the C-terminal tail of SHP1 alone activated the NLS, which in turn led to
the nuclear localization of SHP-1 (Fig. 2). However, fusing EGFP at the N-terminus of SHP-1,
which still hides the NLS in the native protein,
keeps the SHP-1 in the cytoplasm (Fig. 2). The
data suggest that the contradictory observations of the subcellular localization of the
EGFP-fused SHP-1 were due to the different
location of the fused EGFP relative to the Cterminus.
SHP-1 is involved in the EGF-activated
signaling pathway and positively regulates the
EGF-induced STAT activation [Keilhack et al.,
1998; Tenev et al., 2000]. SHP-1 binds to the
EGF receptor via its two SH2 domains and

Fig. 7. Subcellular localization of endogenous SHP-1. Endogenous SHP-1 shows a cytosolic distribution in
all three epithelial cells (A431, HT29, and HepG2) and in a hematopoietic cell line (Raji). [Color figure can be
viewed in the online issue, which is available at www.interscience.wiley.com.]
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dephosphorylates the EGF receptors [Tenev
et al., 1997]. Our results from both immunofluorescence and Western blot analysis have
identified that EGF-stimulation can activate
the NLS of SHP-1, which led to the translocation
of SHP-1 from cytoplasm to nucleus in COS7 cell
lines but not in A431 cell lines (Fig. 5).
It is noteworthy that the translocation of
SHP-1 from cytoplasm to nuclei, in response to
the stimulation of EGF or growth hormone (GH)
is also dependent on cell type. In response to
stimulation, translocation of SHP-1 takes place
in normal cell lines such as COS7 cells, similar
to the observed translocation of SHP-1 in
CWSV-1 cells (rat liver cells) [Gebert et al.,
1997; Ram and Waxman, 1997], but not in
carcinoma cell lines (A431 cells) [Tenev et al.,
2000]. In A431 cells, SHP-1 has a perinuclear
but not nuclear distribution, and the induced
overexpression of SHP-1 leads to the attenuation of EGF receptor auto-phosphorylation and
of EGF-induced DNA binding of STAT1 and
STAT3 [Tenev et al., 2000]. In CWSV-1 cells,
GH also induced the nuclear translocation of
SHP-1 protein, which plays a role in the deactivation of nuclear STAT5b following the termination of a plasma GH pulse in rat liver cells
in vivo. The response time for the translocation
after the EGF- or GH-stimulation is short [Ram
and Waxman, 1997; Tenev et al., 2000], suggesting that SHP-1 is tightly involved in the
signaling pathways. Further evidence for the
translocation of SHP-1 in response to stimulation of cytokines has been obtained with IL-4 or
IL-7 within the mouse fibroblast NIH3T3 cell
lines [Yang et al., 2002]. However, in comparison with the EGF- or GH-stimulation, the
response time to IL-4 or IL-7 stimulation was
much longer (6 h) [Yang et al., 2002].
EGF-stimulation can recruit SHP-1 to bind to
the phosphorylated EGF receptor. SHP-1 then
leads to dephosphorylation of the EGF receptor
in normal cell lines such as COS7 [Yi et al.,
1992]. The binding of EGF receptor to SHP-1
may result in a conformational change of SHP-1
that leads to the activation of the NLS at the Cterminus of SHP-1 that is blocked unless
stimulated (by EGF, in this case). However, in
several tested carcinoma cell lines, different
forms of SHP-1, either endogenous SHP-1 or
different EGFP fused SHP-1, were observed in
the cytoplasm. In those cell lines, EGF stimulation did not target the SHP-1 into nuclei (Fig. 5).
The data suggested that either the signal path-

way regulating the nuclear translocation of
SHP-1 was blocked, or the SHP-1 protein was
kept in cytoplasm or excluded from the nuclei in
the tested cancer cell lines. We have shown that
EGFP-fused with the SHP-1 tail (not the full
length SHP-1), regardless of the orientation,
has nuclear distribution (Fig. 4), which suggests
that the signal pathway for nuclear translocation is normal in the test cancer cells. Nevertheless, binding level of SHP-1 to EGF receptor
may be dependent on cell type, and SHP-1
activity on signaling cascades is varied similarly, depending on the levels and activation
state of critical signaling proteins [Tenev et al.,
1997; You and Zhao, 1997; Keilhack et al., 1998].
In addition, SH2 domains are also thought to
direct the subcellular localization of SHP-1, for
example, through binding to receptors [Eck
et al., 1996; Tenev et al., 1997, 2000]. Thus,
examination of nuclear localization of SHP-1 in
more cell lines will help us better understand
how SHP-1 activity is regulated by its Cterminal tail.
In conclusion, we have shown that an NLS is
located at the C-terminal tail of SHP-1, and is
primarily defined by the three amino-acid
residues KRK at the C-terminus. This NLS
peptide is blocked in the basal state, and can be
activated by EGF stimulation, which results in
the translocation of SHP-1 from cytosol to
nucleus in normal cell lines.
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